Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

31 Mar 2010

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

The Fairbanks Institute for Healthy Communities, the Indianapolis not-for-profit organization working to improve community health, and BioServe, a global provider of biomaterial and genetic research services, today announced that they will co-market INbank™, a next generation biorepository that was recently launched by The Fairbanks Institute.

31 Mar 2010

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

NeurOp Corporation today announced a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused upon the development of NeurOp's proprietary small molecules for use in the treatment of major depression and other central nervous system disorders.

31 Mar 2010

StockPreacher.com releases investment report on MDRNA

StockPreacher.com announces an investment report featuring drug developer MDRNA Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

30 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Maryland Technology Enterprise Institute director receives President's Award

Martha Connolly, director of the Maryland Technology Enterprise Institute Maryland Industrial Partnerships program at the University of Maryland, was given the President's Award at the Greater Baltimore Committee's fifth annual Bioscience Awards ceremony, university officials announce today.

27 Mar 2010

Market update on CBI's planned acquisition of Shanghai-based GL-Biochem

Commonwealth Biotechnologies, Inc. is pleased to provide this market update about its planned acquisition of Shanghai-based GL-Biochem and its associated businesses, one of the largest global suppliers of research-grade peptide products and peptide reagents.

27 Mar 2010

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

Techulon Inc., a life sciences company, has signed worldwide exclusive license agreements with the University of Cincinnati to manufacture and sell novel transfection reagents used for research and therapeutic delivery of nucleic acids.

25 Mar 2010

BeaconEquity.com announces investment report on AEterna Zentaris

BeaconEquity.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

25 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008.

23 Mar 2010

Panel: Management of ocean to enhance human health and reduce public health risks

On Monday, March 22, NOAA's Oceans and Human Health Initiative will host two briefings to key House and Senate staffers on NOAA's efforts to improve understanding and management of the ocean, coasts, and Great Lakes to enhance benefits to human health and reduce public health risks.

20 Mar 2010

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

A collaborative project between Sanford-Burnham Medical Research Institute at Lake Nona and Analiza, Inc. has yielded aqueous solubility data for over 20,000 compounds in the NIH Molecular Library within the first 90 days of screening and characterization.

19 Mar 2010

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

The University of Pennsylvania and AstraZeneca today announced a new collaborative research agreement to make use of their respective talents and resources in an effort to bridge the transition from drug discovery to development.

19 Mar 2010

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE™ technology for delivery of genes into cells.

18 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.

18 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

Ingenuity Systems, the leading provider of information solutions for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece, Turkey and the Balkan countries. IPA is the leading software application to model, analyze, and understand the complex biological and chemical systems at the core of life science research.

17 Mar 2010

Drug Discovery News and Research

Further Reading

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

StockPreacher.com releases investment report on MDRNA

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

Maryland Technology Enterprise Institute director receives President's Award

Market update on CBI's planned acquisition of Shanghai-based GL-Biochem

Tips offered in April 2010 issue of American Journal Of Pathology

Techulon, UC sign worldwide exclusive license agreements to market Glycofect-Transfection Reagent

BeaconEquity.com announces investment report on AEterna Zentaris

Evotec AG reports financial results and corporate updates for 2009

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Panel: Management of ocean to enhance human health and reduce public health risks

Collaborative project yields aqueous solubility data for over 20,000 compounds in NIH Molecular Library

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

Event guide: World ADC London eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®